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Abstract
Background:  Occurrence of atrial fibrillation (AF) amongst bisphosphonate users has been
increasingly reported but results are conflicting. We performed a Bayesian meta-analysis to address
the possible association between the occurrence of AF and bisphosphonate use and estimated the
posterior probability of development of AF with bisphosphonate use.
Methods:  Randomized controlled trials (RCTs) evaluating the efficacy and safety of
bisphosphonates for treating and preventing osteoporosis, and observational studies investigating
the incidence of AF amongst bisphosphonate users, were searched in electronic databases. We
pooled the effect size with Bayesian meta-analysis for odds ratio (OR) and calculated its posterior
probability of development of AF in bisphosphonate users for RCTs and observational studies,
reported with the 95% credible interval (CI).
Results: Of 1751 potentially relevant citations initially retrieved, 4 RCTs and 2 reports of RCTs,
and 3 observational studies were included for this meta-analysis. On pooling the RCTs, there was
a non-significantly higher risk of overall (OR 1.184, 95% CI 0.837-1.656) and serious AF (OR 1.590,
95% CI 0.613-3.751) in bisphosphonate-treated patients. Combining data of observational studies
also revealed a non-significantly higher risk of AF in bisphosphonate users (OR 1.251, 95% CI 0.980-
1.732). Using Bayesian meta-analysis based on the effect size of observational studies as the prior,
the posterior probability of OR>1.2 in the development of AF amongst bisphosphonate users in
the RCTs was 0.484. Egger's regression demonstrated no notable publication bias in all the analyses.
Conclusion: The current meta-analysis revealed no evidence of a higher risk of AF associated with
bisphosphonate use. Nevertheless, based on Bayesian meta-analysis with the effect size of the
observational studies as the prior, the posterior probabilities of development of AF was found to
be 0.484 if the risk of AF was estimated to be more than 20%. The results of the current meta-
analysis thus offer clinicians the practical probability of development of AF in patients who take
bisphosphonates for the treatment of bone loss and corticosteroid induced osteoporosis.
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Background
Bisphosphonates are currently the first-line therapeutic
agents for treating postmenopausal women and men with
osteoporosis, and patients with corticosteroid-induced
osteoporosis [1-5]. While the vast majority of randomized
controlled trial (RCTs) and observational studies demon-
strated that bisphosphonates are both efficacious and
promisingly safe in preserving bone density, preventing
fragility fractures and reducing mortality [6-11], a few
unexpected adverse effects, such as osteonecrosis of the
jaw, hepatotoxity, auditory hallucination and visual dis-
turbance have been increasingly described in the literature
[12-15]. More recently, a RCT evaluating the efficacy and
safety of zoledronic acid in postmenopausal women with
osteoporosis demonstrated an unexpectedly higher risk of
atrial fibrillation (AF) in patients who received the yearly
intravenous zoledronate infusion compared to the con-
trol group [16]. In view of this concern, data from the
Fracture Intervention Trials (FIT) [17] and a few RCTs
involving risedronate [18] have recently been reviewed
and the incidence and risk of AF regarding bisphospho-
nate use were analyzed. Review of these data illustrated a
non-significant increase in the risk of AF in those who
received bisphosphonates than those who received pla-
cebo [17,18]. Besides RCTs, three population based case-
control observational studies addressing the potential
hazard of AF in bisphosphonate use have recently been
published [19-21]. Two of them demonstrated a signifi-
cantly higher risk of AF even after adjustment for potential
confounders [19,21] while the other revealed a non-sig-
nificant trend for development of AF amongst bisphos-
phonate users [20]. Given the relatively insufficient
sample sizes in these studies to observe such a rare event
which was not anticipated at the outset, inconsistency of
results between these studies is not surprising. To over-
come this issue while we are awaiting data of larger RCTs
with longer observational period, it is possible to generate
an estimate of the effect size by pooling the data of the
currently available studies by validated statistical meth-
ods. This strategy will increase the sample size and hence
the power to detect a difference between bisphosphonate
users and non-users with regard to the risk of develop-
ment of AF.
Meta-analysis is a statistical procedure for combining
results of several studies to generate a single estimate of
the major effect with enhanced precision and it is
regarded as a powerful tool for summarizing inconsistent
findings from different studies [22]. In the present meta-
analysis we tried to address whether an excess risk of AF
exists amongst bisphosphonate users by pooling data
from all currently available RCTs and large observational
studies. In addition, we calculated the posterior probabil-
ity of development of AF occurred in a number of clini-
cally practical risks amongst bisphosphonate users based
on the risk observed in observational studies, by using
Bayesian meta-analysis.
Methods
We performed a literature search by using the combina-
tions of the relevant keywords "bisphosphonates",
"zoledronate", "ibandronate", "alendronate", "risedro-
nate", "etidronate", "pamidronate", "clodronate",
"adverse events", "atrial", "atrial flutters" and "atrial fibril-
lation" to identify RCTs and observational studies in full
publications in the English language from different com-
puterized databases: MEDLINE (up to April 2009),
EmBASE (up to April 2009) and the Cochrane Centre Reg-
ister of Controlled Trials (up to April 2009). Abstracts
published in major international rheumatology confer-
ences (Annual European Congress of Rheumatology,
ACR/ARHP Annual Scientific Meeting and Congress of the
Asia Pacific League of Associations for Rheumatology)
over the past 10 years were manually searched. We also
scanned the articles from the bibliographies of retrieved
trials and review articles. We excluded trials which evalu-
ated the efficacy and safety of bisphosphonates other than
for bone loss, osteoporosis, fractures and corticosteroid-
induced osteoporosis. We pre-determined that the corre-
sponding authors should only be contacted by the first
author (A.M.) for essential information which were lack-
ing in the published articles.
For RCTs, all trials which randomly assigned patients to
receive either a bisphosphonate (zoledronate, ibandro-
nate, alendronate, risedronate, etidronate, pamidronate
or clodronate) or placebo for treatment and/or prevention
of bone loss and osteoporosis were retrieved for evalua-
tion. We included those RCTs for analyses if they met the
following criteria: (i) compare a bisphosphonate with a
placebo (ii) administer concomitant therapy with ade-
quate calcium and vitamin D in both groups and (iii)
report the occurrence of AF.
For observational studies, only those which involved con-
trol groups without exposure to bisphosphonates and
reported the proportion of patients with AF on both
bisphosphonate exposed and unexposed groups were eli-
gible because our aim is to identify the risk of AF from
bisphosphonates exposure.
Two investigators (A.M. and A.A.C) independently
assessed the papers generated for relevancy. Papers with
the following exclusion criteria were excluded: (i) not hav-
ing English abstract; (ii) not reporting the occurrence of
AF and (iii) not evaluating the efficacy and safety for the
prevention and/or treatment of bone loss and fragility
fractures. Data were independently extracted into a stand-
ard electronic data extraction form. Any discrepancies
were resolved by consensus. If consensus could not beBMC Musculoskeletal Disorders 2009, 10:113 http://www.biomedcentral.com/1471-2474/10/113
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reached, the principal investigator (A.M.) would make the
final decision for trial eligibility and data extraction. The
second author (M.W.C) provided expert biostatistical
advice while the senior author (C.S.L) was the advisor of
this meta-analysis.
The quality of the RCTs was assessed based on a standard
scoring system suggested by Jadad [23]. The assessment is
based on (i) whether the randomization method is appro-
priate, (ii) whether double blindness is mentioned in the
trial and whether it is appropriate and (iii) whether the
number of patients of and the reasons for withdrawal and
dropouts are clearly stated. The score ranges from 0 to 5
with higher scores denote better quality of a trial.
We performed Bayesian random-effects meta-analysis
with non-informative prior (mu~dnorm(0, 0.0001) and
precision~dgamma(0.001, 0.001)) to pool the effect sizes
of the RCTs and observational studies separately and sum-
marized as odds ratio (OR) of development of AF between
bisphosphonate users and non-bisphosphonate users/
placebo groups, with their corresponding 95% credible
intervals (CI) [24]. The use of non-informative prior
implies that we do not have strong belief on the values of
the pooled effect size in the Bayesian meta-analysis.
Results based on Bayesian meta-analysis with non-
informative prior and classical meta-analysis are very sim-
ilar. One hundred thousand iterations were used in the
Bayesian analysis. There are two advantages of using Baye-
sian meta-analysis in the current study. First, as suggested
by Sutton et al [24] and Ades et al [25], it is possible to
combine findings of RCTs and observational studies by
using the estimates from the observational studies as the
prior. This provides an overall estimate on all RCTs and
observational studies. This estimate is more precise than
that from the RCTs and observational studies. Second,
Bayesian meta-analysis allows us to estimate the posterior
probability of the effect size that is larger than a particular
value. This helps us to estimate the probability of the prac-
tical clinical significance that is larger than a particular
OR. Since the results of Bayesian meta-analysis are sensi-
tive to the priors, we used several priors to check the sen-
sitivity of the findings.
For each meta-analysis we assessed the heterogeneity with
the use of the I2 statistics which describes the percentage
of total variation across studies caused by heterogeneity
rather than chance. High values of I2 suggest increased het-
erogeneity. Publication bias was examined statistically by
Egger's regression test.
All statistical analyses in this meta-analysis were per-
formed using the WinBUGS 1.4.3 [26] and R [27].
To ensure the quality of the meta-analyses, both the
MOOSE (meta-analysis of observational studies in epide-
miology) and QUOROM (quality of reporting of meta-
analysis) guidelines were adhered where applicable
[28,29].
Results
Search results
We initially searched for RCTs on respective bisphospho-
nate and retrieved 1,680 citations through the electronic
databases as described in the Method section. After
excluding review articles (n = 43), author replies (n = 26),
case reports (n = 18), non-English articles (n = 3), non-
RCTs (n = 503), unrelated clinical trials (n = 571), RCTs
not reporting AF (n = 505) and experimental studies (n =
8), 2 RCTs and 1 short communications which included
another 2 RCTs were eligible for the meta-analysis.
Amongst these 4 RCTs, two were testing the efficacy and
safety of zoledronate (the HORIZON Pivotal Fracture
Trial and the HORIZON Recurrent Fracture Trial) [11,16]
and the other two were published as short communica-
tion [17] which consisted of data of the two Fracture inter-
vention Trials [30,31]. We also identified a
communication published as a short report comprising
data of 5 RCTs testing the efficacy and safety of risedronate
[18]. We further identified one abstract comprising 4
RCTs which reported the incidence of AF in ibandronate
users presented in the Annual European Congress of
Rheumatology in June 2008 [32].
We subsequently performed searches for observational
studies reporting bisphosphonates use and AF with the
electronic databases described in the Method section and
identified 71 potential citations. After exclusion of RCTs
(n = 4), unrelated observational studies (n = 28), repeated
quotations (11), review articles (n = 8), author replies (n
= 10), case reports (n = 2) and non-English articles (n = 5),
3 population-based observational studies with case-con-
trol design were eligible for analysis [19-21]. Figure 1
summarizes the results of the literature search.
Summary of the RCTs
For the 4 eligible RCTs (the HORIZON Pivotal Fracture
Trial, the HORIZON Recurrent Fracture Trial and the 2
FIT), 8,152 patients were randomly assigned to receive
bisphosphonates while 8,132 patients received placebo.
For the combined results of the 5 RCTs on risedronate and
4 on ibandronate, 16,848 were randomized to receive
bisphosphonates while 6,972 were not. Table 1 summa-
rizes the characteristics of the RCTs included in the meta-
analysis.
Data of AF reported in the two FIT [30,31] were combined
and published in the form of a report [17]. Since patients
who participated in the FIT were captured in the sameBMC Musculoskeletal Disorders 2009, 10:113 http://www.biomedcentral.com/1471-2474/10/113
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Summary of the literature search Figure 1
Summary of the literature search.
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region and study centres, were postmenopausal female
and observed for a similar mean observation period, the 2
studies of FIT would have contributed comparable vari-
ance if they were separately entered into the meta-analy-
sis. Therefore we decided to assign this report for analysis
as 2 separate RCTs. On the contrary, we did not assign the
2 reports of RCTs involving risedronate [18] and ibandro-
nate [32] for analysis with the two HORZION trials
[11,16] and the two FIT studies [30,31] because (i) the
risedronate and ibandronate studies were of different
designs and some of them compared the efficacy and
safety of widely different dosages of risedronate and iban-
dronate [33,34], and (ii) some of these studies did not
include a placebo group [35,36]. Considerable heteroge-
neity between these risedronate and ibandronate trials is
therefore expected and the variance of each of these trials
is unknown because only combined, rather than data of
individual study, was reported. We therefore decided that
rather than combining all the results of the RCTs, it would
be more appropriate to perform a sensitivity analysis to
test the robustness of the result of the 4 RCTs (the HORI-
ZON Pivotal Fracture Trial, the HORIZON Recurrent Frac-
ture Trial and the other is a report of the 2 FIT) by
comparing with the combined RRs of these 4 RCTs and
the 2 reports respectively on risedronate (consisting of 5
RCTs) and ibandronate (consisting of 4 RCTs).
Summary of the observational studies
In the 3 retrospective population-based observational
case-control studies [19-21], 18,251 patients received
bisphosphonates while 107,792 were not exposed to
bisphosphonates. Two studies retrospectively identified
bisphosphonate users in patients with AF in healthcare
delivery system setting and national registries respectively
[19,20] while the other identified AF in patients and con-
trols with fractures who received bisphosphonates [21].
Although the initial patients of target were different
between these observational studies, their study design
and aim were similar. Table 2 summarizes the characteris-
tics of the eligible population-based case-control studies.
Calculation of the rates of AF in bisphosphonates users 
and non-bisphosphonate users
Unlike the RCTs which clearly stated the number of
patients in the treatment groups and placebo groups who
developed AF, the occurrence of AF in bisphosphonate
users and non-users in the observational case-control
studies were not explicitly stated. Based on the data of
Table 1: Characteristics and quality of randomized control trials comparing bisphosphonates users and controls with regard to atrial 
fibrillation
Author, year *Studies included in 
reports (Ref)
Publication N †AF/BP users versus
AF/non-BP users
Age
(mean)
Study duration
(years)
Jadad
score
(1-5)
Black, 2007 NA Full text 7714 94/3862 versus
73/3852
73 3 4
Cummings, 2007 Black,
1996a (27)
Letter to the 2027 81/3236 versus 70.8 3 4
Cummings, 1998a (28) editor 4432 71/3223 67.7 4.2 3
Lyles, 2007 NA Full text 2111 29/1054 versus
27/1057
74.5 5 4
Karam, 2007 Combination of trials b Letter to the editor 15066 Summary:
189/10018 versus
94/5048
73.5 NA NA
Papapoulous, 2008 Chesnut, 2005 (30) 2929 68.7 3 3
Recker, 2004 (31) Abstract 2860 Summary: 67 3 4
Reginster, 2006 (32) 1583 57/6830 versus
18/1924
66 2 4
Eisman, 2008 (33) 1382 65.9 2 4
*Randomized controlled trials included in letters to the editor and abstracts
† Number of cases of AF in bisphosphonate users versus number of cases of AF in non-bisphosphonate users
a Two Fracture Intervention Trials
b Involved trials: Vertebral Efficacy with Risedronate Therapy Trial, the Bone Mineral Density Trial, the Risedronate
5 mg Daily Prevention Trial, the Glucocorticosteroid - Induced Osteoporosis Prevention and Treatment Trials and the
Hip Intervention Program Trial
Abbreviations: Ref, references; N, number of patients; AF, atrial fibrillation; BP, bisphosphonates; NA, not applicableBMC Musculoskeletal Disorders 2009, 10:113 http://www.biomedcentral.com/1471-2474/10/113
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each observation study, we calculated the occurrence of
AF in bisphosphonates users and non-users as follows: (i)
For Herbeck's study [19], the number of alendronate users
was 87 (47+40). Amongst these 87 patients who were
exposed to the bisphosphonate, 40 of them developed AF.
For those who were not exposed to alendronate (672+926
= 1,598), 672 developed AF. (ii) For Sørensen's study
[20], the number of patients who were ever exposed to
bisphosphonates was 3,862 (435+289+1,958+1,180).
Amongst these 3,862 patients who were exposed to
bisphosphonates, 724 (435+289) of them developed AF.
For those who were not exposed to bisphosphonate
(12862+64781 = 77,643), 12,862 of them developed AF.
(3) For Abrahamsen's study [21], the number of patients
with AF is equal to the number of patients × incidence of
AF (1000 patient years) × mean follow-up time. Therefore
the occurrence of AF in bisphosphonate users = (20.6/
1000) × 2.7 × 14,302 = 797, while that of non-bisphos-
phonate users = (16.5/1000) × 2.7 × 28731 = 1,280.
Table 2: Characteristics of population based case-control studies comparing bisphosphonates users and controls with regard to atrial 
fibrillation
Author, year Publication N †AF/BP users versus
AF/non-BP users
Age (mean) Study duration (years)
Heckbert, 2008 Full text 1685 47/87 versus
672/1598
72.7 3*
Sorensen, 2008 Full text 81505 724/3862 versus 12862/77643 76.1 6**
Abrahamsen, 2009 Full text 43033 797/14302 versus 1280/28731 74.3 10***
† Number of cases of AF in bisphosphonate users versus number of cases of AF in non-bisphosphonate users
* Atrial fibrillation occurred between 1st October 2001 and 31st December 2004
** Atrial fibrillation occurred between 1999 and 2005
***Atrial fibrillation occurred between 1st January 1996 and 31st December 2005
Abbreviations: N, number of subjects in the study; AF, atrial fibrillation; BP, bisphosphonates
Forest plot of the odds ratio of atrial fibrillation: Bisphosphonate users versus controls by pooling *4 RCTs Figure 2
Forest plot of the odds ratio of atrial fibrillation: Bisphosphonate users versus controls by pooling *4 RCTs. 
Abbreviations: RCT, randomized control trial; BP, bisphosphonate; AF, atrial fibrillation; CI, credible interval; RE, random 
effects. *Two RCTs in Cummings et al's study. See text for details.
AF Total AF AF Total AF
BP Non-BP
Observed [95% CI]
 1.18 [  0.84 ,  1.66 ] RE Model
0.39 0.81 1.23 1.66 2.08
Odds Ratio
Lyles, 2007
Cummings, 2007
Black, 2007
29
81
94
1054
3236
3862
27
71
73
1057
3223
3852
 1.08 [  0.63 ,  1.84 ]
 1.14 [  0.83 ,  1.57 ]
 1.29 [  0.95 ,  1.76 ]
* 
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Combined OR of AF from 4 RCTs
Data from 4 RCTs (the HORIZON Pivotal Fracture Trial,
the HORIZON Recurrent Fracture Trial and the 2 FIT of
alendronate) were pooled and the combined estimate
revealed a non-significantly higher risk of AF amongst
patients in the bisphosphonate group compared with
those in the placebo group (OR 1.184, 95% CI 0.837-
1.656) (See Figure 2). As predicted in our assumption dis-
cussed above, I2 statistics showed that these studies were
very homogeneous (Q(df = 2) = 0.466, p = 0.792, I2 = 0).
Egger's regression test revealed no evidence of significant
publication bias in these RCTs (Intercept = -1.196, stand-
ard error (SE) = 1.368, p = 0.543, 2 tailed).
Combined OR of serious AF from 4 RCTs
Cases of serious AF were reported in the RCTs when
patients with AF resulted in hospitalization, disability or
judged to be life threatening [11,16]. When we combined
the RRs of serious AF cases reported in the 4 RCTs (the
HORIZON Pivotal Fracture Trial, the HORIZON Recur-
rent Fracture Trial and the 2 FIT of alendronate), patients
who had bisphosphonates again demonstrated a non-sig-
nificantly higher risk of serious AF compared with those
received placebo (OR 1.590, 95% CI 0.613-3.751) (see
Figure 3). Heterogeneity was relatively substantial as
assessed by the I2 statistics (Q(df = 2) = 5.368, p = 0.068,
I2 = 62.7). Publication bias was not evident as estimated
by Egger's regression test (Intercept = -3.896, SE = 5.207,
p = 0.591, 2 tailed).
Combined OR of AF from observational studies
Combination of the results of the three large population-
based case-control studies revealed that bisphosphonate
users had a non-significantly higher risk of development
of AF compared to non-bisphosphonate users (OR 1.251,
95% CI 0.980-1.732). Heterogeneity between these 3
studies were mild (Q(df = 2) = 3.572, p = 0.168, I2 = 44.0)
(see Figure 4). Egger's regression test revealed no evidence
of significant publication bias in these observational stud-
ies (Intercept = 1.782, SE = 1.574, p = 0.461, 2 tailed).
Combined OR for observational studies and RCTs
According to Sutton et al and Ades at el [24,25], the
pooled OR and its sampling variance from the observa-
tional studies could be used as the prior in the analysis of
RCTs. Ten times the sampling variance of the pooled OR
obtained from the observational studies was used as the
variance of the pooled OR in the prior. This provides a
conservative estimate on the pooled OR and its CI. The
pooled effect size and its 95% CI was OR 1.194, 95% CI
Forest plot of odds ratio of serious atrial fibrillation: Bisphosphonate users versus controls by pooling *4 RCTs Figure 3
Forest plot of odds ratio of serious atrial fibrillation: Bisphosphonate users versus controls by pooling *4 RCTs. 
Abbreviations: RCT, randomized control trial; BP, bisphosphonate; AF, atrial fibrillation; CI, credible interval; RE, random 
effects. * Two RCTs in Cummings et al's study. See text for details.
AF Total AF AF Total AF
BP Non-BP
Observed [95% CI]
 1.59 [  0.61 ,  3.75 ] RE Model
-0.37 0.97 2.31 3.66 5
Odds Ratio
Lyles, 2007
Cummings, 2007
Black, 2007
12
47
50
1054
3236
3862
14
31
20
1057
3223
3852
 0.86 [  0.39 ,  1.86 ]
 1.52 [  0.96 ,  2.39 ]
 2.51 [  1.49 ,  4.23 ]
* 
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0.923-1.540 by combining RCTs with observational stud-
ies. Besides reporting the statistical significance of the
effect size, clinicians are particularly interested in the prac-
tical significance of the findings which indicates whether
the effect size is large enough to be of value in a practical
point of view. The value of practical significance depends
on the specific context. For example, if we define OR>1.2
as the practical significance, by checking the posterior
probability, the estimated probability for OR>1.2 was
0.484. This indicates that the probability of observing a
study with OR>1.2 is about 0.48.
Sensitivity analysis
The sensitivity analysis comprised two parts. First, we con-
firmed the robustness of the combined OR of the 4 RCTs
(the HORIZON Pivotal Fracture Trial, the HORIZON
Recurrent Fracture Trial and the 2 FIT of alendronate) by
comparing it with the OR pooling from these 4 RCTs with
the 2 reports of RCTs (5 on risedronate and 4 on ibandro-
nate). Second, since the results of Bayesian meta-analysis
are sensitive to the priors, we used several priors to check
the sensitivity of the results. To address the sensitivity of
the priors on the results, two priors based on the variance
of the pooled OR of the observational studies were used.
They were the sampling variance of the pooled OR and 10
times of it. The first prior can be considered as a liberal
prior because it puts more weight on the observational
studies. The second prior is more conservative as it puts
less weight on the observational studies.
The result remained robust when the 4 RCTs (the HORI-
ZON Pivotal Fracture Trial, the HORIZON Recurrent Frac-
ture Trial and the 2 FIT of alendronate) and the 2 reports
of RCTs (5 on risedronate and 4 on ibandronate) were
combined (OR 1.096, 95% CI 0.896-1.342). No notable
publication bias was noted (Intercept = -0.477, SE =
1.301, p = 0.738, 2 tailed). (See Figure 5 and Table 3).
The pooled ORs and their 95% CIs for the liberal and the
conservative priors were close, which are OR 1.222, 95%
CI 1.119-1.335 and OR 1.194, 95% CI 0.923-1.540,
respectively. The posterior probabilities of different values
of the practical significance (from OR>1.1 to OR>1.5)
were shown in Table 4. Clinicians may refer to the proba-
bility for the desired level of practical significance.
Discussion
Meta-analysis of RCTs revealed only a trend of higher AF
risk in bisphosphonate users compared with patients on
placebo. The reasons for this non-significant result are
many. First, these RCTs might lack sufficient power to
detect such a rare occurrence of AF. Second, the previously
Forest plot of the odds ratio of atrial fibrillation: Bisphosphonate users versus non-bisphosphonate users by pooling 3 observa- tional studies Figure 4
Forest plot of the odds ratio of atrial fibrillation: Bisphosphonate users versus non-bisphosphonate users by 
pooling 3 observational studies. Abbreviations: BP, bisphosphonate; AF, atrial fibrillation; CI, credible interval; RE, random 
effects.
 1.25 [  0.98 ,  1.73 ] RE Model
0.76 1.27 1.78 2.28 2.79
Odds Ratio
Abrahamsen, 2009
Sorensen, 2008
Heckbert, 2008
797
724
47
14302
3862
87
1280
12862
672
28731
77643
1598
 1.27 [  1.16 ,  1.39 ]
 1.16 [  1.07 ,  1.26 ]
 1.62 [  1.05 ,  2.50 ]
AF Total AF AF Total AF
BP Non-BP
Observed [95% CI]
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reported association between bisphosphonate use and AF
might simply be due to chance, as so far only one RCT
could demonstrate a significant risk of serious AF associ-
ated with bisphosphonate use [16] while other studies
either showed a non-significant trend [17] or even contra-
dictory result [11]. Thirdly, although meta-analysis is a
powerful statistical method to combine study data and
generate an effect size with a greater power, it might not
be the best way to draw conclusion especially when meta-
analysis is based on just a few studies.
The discrepancy in the effect size between overall and seri-
ous AF warrants further discussion. At a closer look at
individual RCT, the odds ratios varied widely between
studies with evidence of opposing directions of the risk
[11,16,17]. The reason of such inconsistency is unclear
although discrepancies in the definition, detection and
reporting of serious AF may play a role. A much higher
heterogeneity (I2 = 62.7) when effect size of serious AF was
pooled compared with that of overall AF (I2 = 0) might
partially explain the possibility we stated.
Similarly, pooling the 3 population-based studies demon-
strated that bisphosphonate users had a non-significantly
higher risk than non-bisphosphonate users for developing
of AF. Results obtained by pooling observational studies
need to be interpreted with caution in that observation
studies are limited by potential confounders which could
not be eliminated when the data were combined in meta-
analysis. Notably, the risk of AF amongst bisphosphonate
users was higher in those with diabetes mellitus and statin
use [19] and likewise, bisphosphonate users were noted to
have a higher rate of antithrombotic and antihypertensive
use in another study [21]. As these factors share a com-
mon risk for atrial fibrillation and osteoporosis which
warrants bisphosphonate use, this further signifies the
presence of potential residual confounding which may
bias the results, even though extensive matching between
Table 3: Result of sensitivity analyses by comparing the combined ORs of *all RCTs and of **4 RCTs
Analysis using all RCTs Analysis using 4 RCTs
Outcome OR (95% CI) df I2 OR (95% CI) df I2
Atrial fibrillation 1.096 (0.896 - 1.342) 4 0.000 1.184 (0.837 - 1.656) 2 0.000
Forest plot of the odds ratio of atrial fibrillation: Bisphosphonate users versus controls by pooling *4 RCTs and **2 reports of  RCTs Figure 5
Forest plot of the odds ratio of atrial fibrillation: Bisphosphonate users versus controls by pooling *4 RCTs and 
**2 reports of RCTs. Abbreviations: RCT, randomized control trial; BP, bisphosphonate; AF, atrial fibrillation; CI, credible 
interval; RE, random effects. * Two RCTs in Cummings et al's study. **Karam 2007 and Papapoulous 2008 are 2 reports of 
RCTs. See text for details
AF Total AF AF Total AF
BP Non-BP
Observed [95% CI]
 1.10 [  0.90 ,  1.34 ] RE Model
0.26 0.72 1.18 1.64 2.1
Odds Ratio
Papapoulous, 2008
aram, 2007
Lyles, 2007
ummings, 2007
Black, 2007
57
189
29
81
94
6830
10018
1054
3236
3862
18
94
27
71
73
1924
5048
1057
3223
3852
 0.89 [  0.52 ,  1.52 ]
 1.01 [  0.79 ,  1.30 ]
 1.08 [  0.63 ,  1.84 ]
 1.14 [  0.83 ,  1.57 ]
 1.29 [  0.95 ,  1.76 ]
C
K
* 
** 
** 
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cases and controls were performed in these observational
studies.
Although statistical significance is important in address-
ing whether an OR is statistically different from unity, it
would be more clinically relevant if clinicians are
informed of the probability of certain risks of develop-
ment of AF in bisphosphonate users. Bayesian meta-anal-
ysis was therefore the method of choice in this study
because (i) it provides an appropriate statistical model to
combine studies of RCTs and observational studies
[24,25] and (ii) it offers the posterior probability which is
practically relevant for clinicians. The major limitation of
the Bayesian meta-analysis is that the results may be sen-
sitive to the priors used. We thus attempted to test the sen-
sitivity of the results by using different priors and our
results showed that the pooled effect size is not sensitive
to the priors used. The point estimate is not very sensitive
to the priors used while the CI and the posterior probabil-
ities of the practical significance are slightly sensitive to
the priors used. This is expected as the number of studies
in this analysis is not large.
While bisphosphonates have been expected to cause gas-
trointestinal side effects and electrolyte disturbance such
as hypocalcaemia, AF is a recently acknowledged and
unanticipated potential adverse event of bisphospho-
nates. Despite being increasingly reported in the litera-
ture, the biological mechanism for AF related to
bisphosphonate use is largely enigmatic. Two putative
mechanisms have been proposed. First, hypocalcaemia
secondary to bisphosphonates intake or infusions might
be a trigger of AF [37]. Since the majority of AF occurred
more than 1 month after bisphosphonate administration
by which time the serum calcium level was normal and
the bisphosphonate level was largely undetectable [16],
AF secondary to hypocalcaemia appears unlikely. Even
though a transient drop of serum calcium level after
administration of bisphosphonates may happen, whether
such a drop of serum calcium can trigger AF is again, elu-
sive.
Alternatively, bisphosphonates, especially when adminis-
trated intravenously, can induce release of pro-inflamma-
tory cytokines such as tumour necrosis factor-alpha (TNF-
α), interleukins-1 and 6 from inflammatory cells. These
inflammatory cytokines may cause remodelling of the
atrium, tissue organisation, fibrosis and subsequent
development of AF [38,39]. Because the majority of AF
occurred at a considerable period of time after administra-
tion of bisphosphonates, the latter mechanism seems
more probable. Without doubt, laboratory studies and
human studies involving more patients are required to
establish the possible pathological relationship between
bisphosphonates and AF.
Although meta-analysis is a strong tool and we have taken
the necessary precautions to detect publication bias and
eliminate the effect of heterogeneity by using the random
effects model for all the analyses, there are still limitations
of the current study and some of them are intrinsic to
meta-analysis. First, the occurrence of AF in patients who
received bisphosphonates is low (incidence around 2%)
and the duration of RCTs is short. Compounded with the
insufficiency of patients participating in the trials, meta-
analysis of RCTs might not be the best method to detect
the possible association between bisphosphonate use and
such a rare event as AF. Second, the current meta-analysis
was based on a few studies only and it is subjected to ran-
dom error. Third, while publication bias was not signifi-
cant statistically in these studies, such a bias can never be
completely eliminated even though we have included
publications in the forms of abstract and letters to the edi-
tor. Fourth, current evidence seems to advocate the possi-
ble role of bisphosphonate potency on the occurrence of
AF [16,18,19,21]. In the present meta-analysis; however,
Table 4: Posterior probability of effect sizes larger than specific odds ratio
Odds ratio *Liberal prior: mu~dnorm(0.2044, 430) *Conservative prior:
mu ~dnorm(0.2044, 10)
>1.1 .990 .753
>1.2 .655 .484
>1.3 .084 .241
>1.4 .001 .098
>1.5 .000 .037
*Prior distribution was obtained from the posterior distribution of the Bayesian meta-analysis on the observational studies. The inverse of the 
estimated variance was used as the prior in the liberal prior condition while the inverse of ten times of the estimated variance was used as the prior 
in the conservative condition.BMC Musculoskeletal Disorders 2009, 10:113 http://www.biomedcentral.com/1471-2474/10/113
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we were not able to separately analyse the risk of AF for
individual bisphosphonate because the dearth of data dis-
allows meaningful analysis. For the same reason, the
number of studies is insufficient to perform meaningful
meta-regression analyses, a statistical procedure to detect
covariate(s) which may explain the heterogeneity between
studies. Fifth, AF was not determined prior to taking
bisphosphonates in the majority of the patients, therefore
whether the occurrence of AF was truly the result of
bisphosphonate intake is unknown. Finally, in order to
maintain homogeneity of the studies for the meta-analy-
ses and minimize the confounding effect of the underly-
ing conditions on the development of AF, we only
included studies which evaluated the use of bisphospho-
nates in patients with bone loss and fractures. As a result,
the cardiovascular adverse effects of bisphosphonate use
in other conditions, such as malignancy, hypercalcaemia
and metabolic bone diseases, were not assessed because
these conditions may also be culprits of arrhythmias. Nev-
ertheless, the precautions we implemented should render
the current meta-analysis the latest available evidence to
date which serves to alert clinicians to seriously consider
the risk of AF and be informed the probability of certain
risks of developing AF in their patients who are taking
bisphosphonates.
While not being a primary objective of this study, the
results underscore the potential limitation of meta-analy-
sis of RCTs in detecting the association between treatment
and rare treatment-related events. At this juncture; concur-
ring with the FDA safety review report [40], physicians
should not refrain from prescribing bisphosphonates to
patients who are truly indicated for the medication. As AF
can be potentially serious, physicians must be alerted
should their patients who are taking bisphosphonate
develop new cardiovascular or respiratory symptoms
which may be secondary to AF.
Conclusion
Bisphosphonate use was not associated with a signifi-
cantly higher risk of AF when RCTs and observational
were collectively analyzed. Nevertheless, based on Baye-
sian meta-analysis, the posterior probabilities of develop-
ment of AF was found to be 0.484 if the risk of AF, based
on the effect size of the observational studies, was esti-
mated to be more than 20%. The results of the current
meta-analysis offer clinicians the practical probability of
development of AF in patients who need bisphospho-
nates for the treatment of bone loss and corticosteroid
induced osteoporosis.
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